CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
-8.73%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$2.56B
AUM Growth
+$2.56B
(-26%)
Cap. Flow
-$400M
Cap. Flow
% of AUM
-15.58%
Top 10 Holdings %
Top 10 Hldgs %
43.81%
Holding
134
New
13
Increased
7
Reduced
67
Closed
28
Top Buys
| 1 |
Monte Rosa Therapeutics
GLUE
|
$69.6M |
| 2 |
Biomea Fusion
BMEA
|
$48.4M |
| 3 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$47M |
| 4 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$44.6M |
| 5 |
VERV
Verve Therapeutics
VERV
|
$40.6M |
Top Sells
| 1 |
C4 Therapeutics
CCCC
|
$80.8M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$64.2M |
| 3 |
Novavax
NVAX
|
$45.3M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$43.6M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$32.8M |
Sector Composition
| 1 | Healthcare | 99.14% |
| 2 | Financials | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
APTO
51
DELISTED
Aptose Biosciences, Inc.
APTO
| $12.6M | 0.43% |
3,807,200
-192,800
| -5% | -$641K |
|
52
GH Research
GHRS
$870M
| $12.6M | 0.43% |
+608,123
| New | +$12.6M |
|
|
MYOV
53
DELISTED
Myovant Sciences Ltd.
MYOV
| $12.4M | 0.42% |
542,499
-457,501
| -46% | -$10.4M |
|
54
Repare Therapeutics
RPTX
$73.9M
| $11.3M | 0.39% |
363,766
-98,439
| -21% | -$3.07M |
|
55
Eledon Pharmaceuticals
ELDN
$155M
| $11.2M | 0.38% |
1,415,500
| – | – |
|
|
MORF
56
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $10.9M | 0.37% |
189,774
-160,226
| -46% | -$9.2M |
|
|
HGEN
57
DELISTED
HUMANIGEN, INC.
HGEN
| $10.4M | 0.35% |
600,000
-400,000
| -40% | -$6.95M |
|
58
AnaptysBio
ANAB
$630M
| $9.99M | 0.34% |
385,081
-264,919
| -41% | -$6.87M |
|
59
Ascendis Pharma
ASND
$12.1B
| $9.87M | 0.34% |
75,000
-25,000
| -25% | -$3.29M |
|
60
Zai Lab
ZLAB
$3.48B
| $9.46M | 0.32% |
53,455
-96,545
| -64% | -$17.1M |
|
61
Inspire Medical Systems
INSP
$2.53B
| $9.3M | 0.32% |
48,132
-36,868
| -43% | -$7.13M |
|
62
Tango Therapeutics
TNGX
$745M
| $9.1M | 0.31% |
800,000
| – | – |
|
63
Galecto
GLTO
$3.93M
| $8.87M | 0.3% |
1,753,839
-396,893
| -18% | -$2.01M |
|
|
TCRR
64
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $7.87M | 0.27% |
479,506
-420,494
| -47% | -$6.9M |
|
|
HARP
65
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $7.5M | 0.25% |
540,600
-30,000
| -5% | -$416K |
|
66
Astria Therapeutics
ATXS
$394M
| $7.49M | 0.25% |
+3,550,000
| New | +$7.49M |
|
|
ITOS
67
DELISTED
iTeos Therapeutics
ITOS
| $7.4M | 0.25% |
288,330
-11,670
| -4% | -$299K |
|
68
ARS Pharmaceuticals
SPRY
$1.08B
| $7.39M | 0.25% |
239,099
-260,901
| -52% | -$8.06M |
|
69
uniQure
QURE
$954M
| $7.38M | 0.25% |
239,548
-10,452
| -4% | -$322K |
|
70
Insmed
INSM
$30.3B
| $7.12M | 0.24% |
250,000
-50,000
| -17% | -$1.42M |
|
71
Veru
VERU
$48.5M
| $6.46M | 0.22% |
800,000
-2,200,000
| -73% | -$17.8M |
|
72
Viridian Therapeutics
VRDN
$1.59B
| $6.27M | 0.21% |
342,962
-116,182
| -25% | -$2.13M |
|
73
Merus
MRUS
$5.04B
| $6.01M | 0.2% |
285,096
-64,904
| -19% | -$1.37M |
|
|
LENZ
74
LENZ Therapeutics
LENZ
$1.12B
| $5.93M | 0.2% |
+203,153
| New | +$5.93M |
|
|
AVEO
75
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $5.89M | 0.2% |
893,500
-606,500
| -40% | -$4M |
|